While President Donald Trump is betting on lower prescription drug prices, a number of payers reportedly have a less optimistic forecast for the future.
According to a STAT report, a new survey by Cowen analysts suggests more than two dozen payers believe per-unit purchasing costs will see anywhere between 3 to 5 percent annual growth over the next three years.
Thirteen percent of the payers point toward newer, high-cost drugs as a driving factor of their expectations.
Click here to read the full report on STAT. (Paid subscription required)